Contineum Therapeutics (CTNM) Return on Equity (2023 - 2025)
Contineum Therapeutics has reported Return on Equity over the past 3 years, most recently at 0.34% for Q3 2025.
- Quarterly results put Return on Equity at 0.34% for Q3 2025, down 17.0% from a year ago — trailing twelve months through Sep 2025 was 0.34% (down 17.0% YoY), and the annual figure for FY2024 was 0.65%, changed.
- Return on Equity for Q3 2025 was 0.34% at Contineum Therapeutics, down from 0.32% in the prior quarter.
- Over the last five years, Return on Equity for CTNM hit a ceiling of 0.17% in Q3 2024 and a floor of 0.44% in Q2 2024.
- Median Return on Equity over the past 3 years was 0.29% (2025), compared with a mean of 0.29%.
- Biggest five-year swings in Return on Equity: increased 14bps in 2024 and later decreased -17bps in 2025.
- Contineum Therapeutics' Return on Equity stood at 0.35% in 2023, then skyrocketed by 41bps to 0.21% in 2024, then plummeted by -63bps to 0.34% in 2025.
- The last three reported values for Return on Equity were 0.34% (Q3 2025), 0.32% (Q2 2025), and 0.26% (Q1 2025) per Business Quant data.